Insights from a rare myeloproliferative neoplasm with coexisting BCR-ABL1 fusion gene, CALR and TET2 mutations treated with nilotinib and ruxolitinib

Li Huo,Jundan Xie,Qian Wang,Hongjie Shen,Zixuan Ding,Lijun Wen,Zhao Zeng,Yi Xu,Changgeng Ruan,Suning Chen,Mengxing Xue

CLINICAL CASE REPORTS（2022）

引用 0|浏览5

暂无评分

摘要

Myeloproliferative neoplasms (MPNs) with concurrent BCR-ABL1 fusion gene and CALR mutation are especially rare.We report a patient with coexisting BCR-ABL1 fusion gene, CALR and TET2 mutations who was treated with the combination of the second-generation TKI nilotinib and JAK1/JAK2 inhibitor ruxolitinib.

查看译文

关键词

BCR-ABL1 fusion gene,CALR mutation,myeloproliferative neoplasms,nilotinib,ruxolitinib

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要